title: Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patients.
abstract: Microarray-based gene expression analysis was performed on diagnostic chronic phase CML patient samples prior to interferon treatment. Fifteen patient samples corresponding to six cytogenetic responders and nine non-responders were included. Genes differentially expressed between responder and non-responder patients were listed and a subsequent leave-one-out cross validation (LOOV) procedure showed that the top 20 genes allowed the highest prediction accuracy. The relevant genes were quantified by real-time PCR that supported the microarray results. We conclude that it might be possible to use gene expression analysis to predict future response to interferon in CML diagnostic samples.
authors.affiliation: Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University Hospital, SE-751 85 Uppsala, Sweden.
authors.forename: Anette
authors.initials: A
authors.lastname: Hagberg
authors.forename: Ulla
authors.initials: U
authors.lastname: Olsson-Strömberg
authors.forename: Ulrika
authors.initials: U
authors.lastname: Wickenberg-Bolin
authors.forename: Hanna
authors.initials: H
authors.lastname: Göransson
authors.forename: Anders
authors.initials: A
authors.lastname: Isaksson
authors.forename: Mats
authors.initials: M
authors.lastname: Bengtsson
authors.forename: Martin
authors.initials: M
authors.lastname: Höglund
authors.forename: Bengt
authors.initials: B
authors.lastname: Simonsson
authors.forename: Gisela
authors.initials: G
authors.lastname: Barbany
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D003561:Cytarabine / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D020869:Gene Expression Profiling; D015973:Gene Expression Regulation, Leukemic; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000097:blood / Q000235:genetics / Q000302:isolation & purification; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D016898:Interferon-alpha; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D003561:Cytarabine; D016044:Fusion Proteins, bcr-abl; D006918:Hydroxyurea